The Association of the British Pharmaceutical Industry (ABPI) represents
innovative research-based biopharmaceutical companies, large, medium and small,
leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
Following a number of years of success working with pharmacy groups, Novartis approached LPCs and the PSNC to facilitate NHS-commissioning of flu vaccination to pharmacies. In 2012 a means of managing a large volume of users and providing them with a professional training course was required, with as much delivered online as possible. The objectives were to recruit and train PCTs and pharmacies and deliver a high number of vaccinations to patients. The results exceeded expectations and pharmacists rated the online platform: 4.46 for ease of use; 4.51 for comprehensivemess of learning content; 4.2 for overall enjoyment (4 = very good; 5 = excellent).
This is a very comprehensive, well structured programme that meets a clear NHS need. Results have been excellent to date and it's still early days so lots of potential for the future.
In an effort to improve patient outcomes, AstraZeneca is collaborating with the NHS on a Joint Working initiative to improve patients' self-management of their underlying disease. Designed for patients with acute coronary syndromes (ACS) prescribed an oral antiplatelet (OAP) therapy, the OneHeart Joint Working support programme seeks to tackle the troubling fact that half of UK patients discontinue OAP treatment within 12 months of discharge from hospital – almost doubling their chance of dying or having a non-fatal heart attack. Summed up by a consultant cardiologist at Bristol Heart Institute, "OneHeart has facilitated a greater understanding of the issues affecting non-adherence in our patients and has integrated more extensive patient support to address the problem. We are already seeing benefits for the patients enrolled into the programme and we look forward to further evaluation." Since launch the OneHeart Joint Working support programme has been extended to a further six hospitals and another twenty are planned over the next year.
South Central SHA wanted to reduce emergency admissions by monitoring and supporting patients with COPD. The strategy was to automate three activities: monitoring symptoms, triaging need and alerting clinicians according to risk level. Patients' average age at diagnosis is 67 so the digital solution chosen was the telephone. The objective was to automatically, twice a week, ask patients pre-set questions to evaluate their symptoms and parse their answers using a clinical algorithm. The system would then automatically alert clinicians if a patient's state of health had deteriorated, enabling early intervention and so avoid admissions. In evaluations to date patients have recorded less severe symptoms, reduced anxiety and depression and excellent patient experience. The COPD Monitor was shown to contribute to patients' self-management, improve their awareness of symptoms of potential exacerbation, improve adherence to treatment and decrease their visits to hospital and GPs. The capacity of clinical staff was also increased by allowing them to focus on the patients at risk. Per patient year COPD Monitor delivers healthcare expenditure savings of £1572 for a cost of only £26.